Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Aug 4;7(3):67.
doi: 10.1208/pt070367.

Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan

Affiliations

Thermoreversible-mucoadhesive gel for nasal delivery of sumatriptan

Rita J Majithiya et al. AAPS PharmSciTech. .

Abstract

The purpose of the present study was to develop intranasal delivery systems of sumatriptan using thermoreversible polymer Pluronic F127 (PF127) and mucoadhesive polymer Carbopol 934P (C934P). Formulations were modulated so as to have gelation temperature below 34 degrees C to ensure gelation at physiological temperature after intranasal administration. Gelation temperature was determined by physical appearance as well as by rheological measurement. The gelation temperatures of the formulations decreased by addition of increasing concentrations of Carbopol (ie, from 29 degrees C for 18% PF127 to 23.9 degrees C for 18% PF127, 0.5% Carbopol). The mucoadhesive force in terms of detachment stress, determined using sheep nasal mucosal membrane, increased with increasing concentration of Carbopol. The results of in vitro drug permeation studies across sheep nasal mucosa indicate that effective permeation coefficient could be significantly increased by using in situ gelling formulation with Carbopol concentration 0.3% or greater. Finally, histopathological examination did not detect any damage during in vitro permeation studies. In conclusion, the PF127 gel formulation of sumatriptan with in situ gelling and mucoadhesive properties with increased permeation rate is promising for prolonging nasal residence time and thereby nasal absorption.

PubMed Disclaimer

References

    1. Fowler PA, Lacey LF, Thomas M, Keene ON, Tanner RJ, Baber NS. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol. 1991;31:291–294. doi: 10.1159/000116756. - DOI - PubMed
    1. Ryan R, Elkind A, Baker CC, Mullican W, DeBussey S, Asgharnejad M. Sumatriptan, nasal spray for the acute treatment of migraine: results of two clinical studies. Neurology. 1997;49:1225–1230. - PubMed
    1. Vyas TK, Babbar AK, Sharma RK, Singh S, Mirsa A. Preliminary brain-targeting studies on intranasal, mucoadhesive microemulsions of sumatriptan. AAPS PharmSciTech. 2006;7:E8–E8. doi: 10.1208/pt070108. - DOI - PubMed
    1. Zhou M, Donovan MD. Intranasal mucociliary clearance of putative bioadhesive polymer gels. Int J Pharm. 1996;135:115–125. doi: 10.1016/0378-5173(96)04441-9. - DOI
    1. Illum L. Bioadhesive formulations for nasal peptide delivery. In: Mathiowitz E, Chickering DE, Lehr CM, editors. Bioadhesive Drug Delivery Systems. New York, NY: Marcel Dekker; 1999. pp. 507–562.

Publication types

MeSH terms

LinkOut - more resources